Extensive research has identified small molecule compounds, including the organosilicon compound DCZ0858 and the JAK2 inhibitor TG101209, as agents capable of exerting anti-lymphoma effects by modulating the JAK2/STAT3 signaling pathway (Xu et al., 2022; Zhang et al., 2021a; Lu et al., 2020). Here, JAK2 is linked to lymphoma.